1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Genetic, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
American Journal of Cancer Prevention.
2017,
Vol. 5 No. 3, 37-38
DOI: 10.12691/ajcp-5-3-3
Copyright © 2017 Science and Education PublishingCite this paper: Mehrdad Payandeh, Afshin Karami, Noorodin Karami. Two Different Faces from Unicentric Castleman Disease (UCD): A Case Series.
American Journal of Cancer Prevention. 2017; 5(3):37-38. doi: 10.12691/ajcp-5-3-3.
Correspondence to: Noorodin Karami, Department of Genetic, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email:
noorodin.karami@yahoo.comAbstract
Castleman disease is a rare lymphoproliferative disorder that was first reported in 1954. The most common type is unicentric and is a benign form of lymphatic disorders, which its treatment has been successfully reported. The etiology of this disease is still unclear, but there is a relationship between this disorder and overproduction of IL- 6. In our study, after treating one of the patients with UCD, due to the unexpected transformation of this disease to DLBCL, the new treatment was performed with combination chemotherapy and is still ongoing. We suggest continuous follow-up of patients during and after treatment. As well, more investigations are needed on the pathogenesis of disease that will lead to better treatment for these patients.
Keywords